Australian paramedics are leading the world by introducing a new drug, droperidol, to quickly and safely calm violent patients fueled by alcohol and drugs. The world's first comparison of the standard sedative, midazolam, with droperidol, was conducted.

QAS found droperidol sedated patients nearly 70% quicker, was three times safer and significantly fewer patients needed additional sedation either in the ambulance or once in hospital in comparison to midazolam.

Within a week of the data being published, QAS had received requests for further information from ambulance services in the United Kingdom and New Zealand, according to QAS Executive Manager Clinical Policy Development, Lachlan Parker ASM.

"Midazolam is the accepted standard internationally, but it can have significant side-effects, so there's been a huge gap in paramedics' ability to safely sedate violent patients," said Mr Parker.

"Our paramedics and emergency department staff welcome the impact droperidol is having, and there are some amazing stories of how it quickly it works to calm aggressive and violent patients," said Mr Parker.

Queensland Minister for Health and Ambulance Services Steven Miles said research projects just like this pave the way for positive change across the healthcare system.

"Sadly, there are thousands of incidents each year where frontline healthcare workers are subject to violent outbursts, mostly as a result of alcohol and drug abuse," he said.

"It's fantastic to see Queensland research making a positive impact in protecting our first responders and emergency department clinicians. Projects like this highlight the importance of investing in medical research and finding new, more effective and more efficient ways of providing vital health services to Queenslanders."

The QAS introduced droperidol in 2016 as one of several initiatives to reduce the escalating violence against paramedics, mostly by drunken patients. Mr Parker championed the uptake of droperidol based on research involving Princess Alexandra Hospital emergency physician and clinical toxicologist, Dr Colin Page.

Dr Page, who has $450,000 Noel Stevenson Fellowship from EMF, led the evaluation of the QAS droperidol roll out. Dr Page said the real value of this latest research was in confirming that droperidol was safer and more effective in the prehospital setting, which mirrored previous results in the emergency department environment.

"The days of repeated doses of midazolam being given by paramedics are over, it just takes too long to sedate patients using this drug, and it is more dangerous," he said.

"We're now pushing for paramedics and clinicians to administer the droperidol intramuscularly there is no need for people to use it intravenously – and to stop mixing different sedatives," said Dr Page.

"Based on our extensive research, the standard protocol for violent patients should be 10 mg droperidol (65 to 75% effective) followed by a second dose of 10 mg (which is 95% effective) and then ketamine," he said.

EMF Chair, Dr Anthony Bell said the QAS-led research showed the importance of evaluating changes in treatment protocols. "A Queensland-led initiative is set to change treatment protocols globally and lead to better patient care because there was research funding available for an evaluation," said Dr Bell.